SEQUENCE LISTING

<110> GENENTECH, INC. ET AL.

<120> METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND VEGF ANTAGONISTS

<130> P4926R1-WO

<140>
<141>

<150> 61/653,861
<151> 2012-05-31

<160> 37

<170> PatentIn version 3.5

<210> 1
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (6)..(6)
<223> Asp or Gly

<220>
<223> see specification as filed for detailed description of substitutions and preferred embodiments

<400> 1
Gly Phe Thr Phe Ser Xaa Ser Trp Ile His
1 5 10

<210> 2
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Ser or Leu

<220>
<221> MOD_RES
<222> (10)..(10)
<223> Thr or Ser

<220>
<223> see specification as filed for detailed description of substitutions and preferred embodiments

<400> 2

Ala Trp Ile Xaa Pro Tyr Gly Gly Ser Xaa Tyr Tyr Ala Asp Ser Val
1 5 10 15

Lys Gly

<210> 3
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 3
Arg His Trp Pro Gly Gly Phe Asp Tyr
1 5

<210> 4
<211> 25
<212> PRT
<213> Homo sapiens

<400> 4
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser
20 25

<210> 5
<211> 13
<212> PRT
<213> Homo sapiens

<400> 5
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
1 5 10

<210> 6
<211> 32
<212> PRT
<213> Homo sapiens

<400> 6
Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln
1 5 10 15

Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> 7
<211> 11
<212> PRT
<213> Homo sapiens

<400> 7
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala
1 5 10

<210> 8
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Asp or Val

<220>
<221> MOD_RES
<222> (6)..(6)
<223> Val or Ile

<220>
<221> MOD_RES
<222> (7)..(7)
<223> Ser or Asn

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Ala or Phe

<220>
<221> MOD_RES
<222> (10)..(10)
<223> Val or Leu

<220>
<223> see specification as filed for detailed description of substitutions and preferred embodiments

<400> 8
Arg Ala Ser Gln Xaa Xaa Xaa Thr Xaa Xaa Ala
1 5 10

<210> 9
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Phe or Thr

<220>
<221> MOD_RES
<222> (6)..(6)
<223> Tyr or Ala

<220>
<223> see specification as filed for detailed description of

substitutions and preferred embodiments

<400> 9
Ser Ala Ser Xaa Leu Xaa Ser
1 5

<210> 10
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Tyr, Gly, Phe or Ser

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Leu, Tyr, Phe or Trp

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Tyr, Asn, Ala, Thr, Gly, Phe or Ile

<220>
<221> MOD_RES
<222> (6)..(6)
<223> His, Val, Pro, Thr or Ile

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Ala, Trp, Arg, Pro or Thr

<220>
<223> see specification as filed for detailed description of substitutions and preferred embodiments

<400> 10
Gln Gln Xaa Xaa Xaa Xaa Pro Xaa Thr
1 5

<210> 11
<211> 23
<212> PRT
<213> Homo sapiens

<400> 11
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys
20

<210> 12
<211> 15
<212> PRT

<213> Homo sapiens

<400> 12
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
1 5 10 15

<210> 13
<211> 32
<212> PRT
<213> Homo sapiens

<400> 13
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
20 25 30

<210> 14
<211> 11
<212> PRT
<213> Homo sapiens

<400> 14
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
1 5 10

<210> 15
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 15
Gly Phe Thr Phe Ser Asp Ser Trp Ile His
1 5 10

<210> 16
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 16
Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
1 5 10 15

Lys Gly

<210> 17
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 17
Arg Ala Ser Gln Asp Val Ser Thr Ala Val Ala
1 5 10

<210> 18
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 18
Ser Ala Ser Phe Leu Tyr Ser
1 5

<210> 19
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 19
Gln Gln Tyr Leu Tyr His Pro Ala Thr
1 5

<210> 20
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 20
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ser
20 25 30

Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Arg His Trp Pro Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ala
115

<210> 21
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 21
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Thr Ala
20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Leu Tyr His Pro Ala
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105

<210> 22
<211> 123
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 22
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30

Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60

Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val
100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 23
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 23
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45

Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105

<210> 24
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

peptide

<400> 24
Gly Tyr Thr Phe Thr Asn Tyr Gly Met Asn
1 5 10

<210> 25
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 25
Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe Lys
1 5 10 15

Arg

<210> 26
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 26
Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val
1 5 10

<210> 27
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 27
Ser Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn
1 5 10

<210> 28
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 28
Phe Thr Ser Ser Leu His Ser
1 5

<210> 29

<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 29
Gln Gln Tyr Ser Thr Val Pro Trp Thr
1 5

<210> 30
<211> 25
<212> PRT
<213> Homo sapiens

<400> 30
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser
20 25

<210> 31
<211> 13
<212> PRT
<213> Homo sapiens

<400> 31
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
1 5 10

<210> 32
<211> 32
<212> PRT
<213> Homo sapiens

<400> 32
Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln
1 5 10 15

Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> 33
<211> 11
<212> PRT
<213> Homo sapiens

<400> 33
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala
1 5 10

<210> 34
<211> 23
<212> PRT
<213> Homo sapiens

<400> 34
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys
20

<210> 35
<211> 15
<212> PRT
<213> Homo sapiens

<400> 35
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
1 5 10 15

<210> 36
<211> 32
<212> PRT
<213> Homo sapiens

<400> 36
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
20 25 30

<210> 37
<211> 11
<212> PRT
<213> Homo sapiens

<400> 37
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
1 5 10